There are 413 resources available
35P - SNPs of aromatase gene (CYP19A1) and outcomes of patients with estrogen receptor-positive (ER+) early breast cancer (eBC) treated with aromatase inhibitors (AIs): a multicenter, prospective study
Presenter: Benedetta Conte
Session: Poster viewing and lunch
36P - Megestrol Acetate resistance in Estrogen Receptor Positive Advanced Breast Cancer in the MEGA trial
Presenter: Bruno Paula
Session: Poster viewing and lunch
37P - Enhanced tumor-immunity drives resistance to CDK4/6 inhibitors in advanced breast cancer
Presenter: Milana Bergamino
Session: Poster viewing and lunch
38P - Assessment of lipidomic profile in Endocrine Receptor positive (ER+) MBC patients treated with CDK 4/6 inhibitors (CDKi) and endocrine therapy (ET).
Presenter: Alessandra Gennari
Session: Poster viewing and lunch
39P - A validation study of a self-testing capillary kit, the rhelise™ kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients
Presenter: Elham Hedayati
Session: Poster viewing and lunch
40P - Stromal tumor infiltrating lymphocytic infiltration in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC)
Presenter: Anirudh Pabba
Session: Poster viewing and lunch
41P - Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model
Presenter: Matthew VandeKopple
Session: Poster viewing and lunch
42P - Conflicting results of BCL2 based on HER2 status in patients with breast cancer.
Presenter: Airi Han
Session: Poster viewing and lunch
43P - AKT and estrogen receptor (ER) inhibition potently impairs endocrine resistance (EndoR) in breast cancer (BC)
Presenter: Agostina Nardone
Session: Poster viewing and lunch
44P - Comparison of biological characteristics in relation to survival in luminal invasive lobular vs invasive non-lobular breast carcinomas
Presenter: Chaido Chamalidou
Session: Poster viewing and lunch